Presented by:
Romaine Charles Nichols, Jr., MD
Associate Professor, University of Florida Department of Radiation Oncology
UF Health Proton Therapy Institute
Faculty Disclosure:
Romaine Charles Nichols, Jr., MD, has disclosed that he has no relevant financial relationships. No one else in a position to control content has any financial relationships to disclose. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. All relevant financial relationships have been mitigated.
Release Date: August 19, 2021
Expiration Date: August 19, 2022
Target Audience: This course is intended for an audience of specialty physicians, primary care physicians, physician assistants, nurses, as well as others who treat patients with lung cancer.
Learning Objectives:
As a result of participation in this activity, participants should be able to:
- Discuss best practices of the use of proton therapy for lung cancer based on current research.
- Define proton therapy and describe how proton therapy is different from conventional radiation therapy.
- Identify and determine the theoretical advantages to the use of proton therapy in the treatment of lung cancer.
Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.
Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Resource(s) for further study:
- Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared withthree-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer.Int J Radiat Oncol Biol Phys. Jul 15 2006;65(4):1087-1096.
- Nichols RC, Huh SH, Hoppe BS, et al. Protons safely allowcoverage of high-risk nodes for patients with regionally advanced non-small-cell lung cancer. Technol Cancer Res Treat.Aug 2011;10(4):317-322.
- Hoppe BS, Flampouri S, Henderson RH, et al. Proton therapy with concurrent chemotherapyfor non-small-cell lung cancer: technique and early results. Clin Lung Cancer. Sep 2012;13(5):352-358.
- Zhang X, Li Y,Pan X, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulatedradiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stageIIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys. Jun 1 2010;77(2):357-366.
- ChangJY, Verma V, Li M, et al. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. Aug 10 2017;3(8):e172032.
[LINK TO CME VIDEO/ACTIVITY] – Will be sent a couple days after the live event.
[LINK TO POST TEST] – Test questions will be sent closer to the date of the CME>
If you have any questions please feel free to contact Christina Mershell at education@floridaproton.org or 904-831-4034.